CorMedixvsJohnson & Johnson

CRMD and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

CorMedix (CRMD) has a market value of $371M and Johnson & Johnson (JNJ) $642B. Over the last year, with dividends, CRMD moved -53.4% and JNJ +36.1%. The P/E is 5.8 for CRMD and 39.9 for JNJ. Dividend yield: CRMD none, JNJ 1.98%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    CRMD$371M

    JNJ$642B

    JNJ is 1,731 times CRMD

  • Revenue, 12 months

    CRMD$412M

    JNJ$99.3B

    JNJ is 241 times CRMD

  • Net income, 12 months

    CRMD$64M

    JNJ$16.1B

    JNJ is 252 times CRMD

  • Operating margin

    CRMD38.6%

    JNJ–

  • ROIC

    CRMD27.3%

    JNJ12.4%

    14.9 points apart

  • P/E

    CRMD5.8

    JNJ39.9

    JNJ is 6.9 times CRMD

  • Dividend yield

    CRMD0.0%

    JNJ2.0%

    2.0 points apart

  • 5-year return

    CRMD-5.1%

    JNJ+88.4%

    93.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

CRMD-5.1%

JNJ+88.4%

10020030020222023202420252026
Returns by period
PeriodCRMDWith dividendsJNJWith dividends
1 year since November 18, 2025-53.4%Price -53.4%+36.1%Price +33.1%
3 years since November 17, 2023+17.2%+5.4% a yearPrice +17.2%+93.5%+24.6% a yearPrice +77.7%
5 years since November 18, 2021-5.1%-1.0% a yearPrice -5.1%+88.4%+13.5% a yearPrice +63.9%
10 years since November 21, 2016-45.3%-5.9% a yearPrice -45.3%+201.6%+11.7% a yearPrice +131.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

CRMDCorMedixJNJJohnson & Johnson

Valuation

CRMDJNJ
Valuation
Price$4.69$266.30
Market value$371M$642B
Enterprise value (EV)$16M$669B
P/E5.839.9
P/E, 5-year median–21.9
P/B0.87.9
EV/EBIT0.137.7
Free cash flow yield83.0%3.2%

Results and growth

CRMDJNJ
Results and growth
Revenue, 12 months$412M$99.3B
Net income, 12 months$64M$16.1B
Free cash flow, 12 months$308M$20.6B
Earnings per share, 12 months$0.81$6.59
Revenue growth, year on year617.0%6.1%
Revenue growth a year, past+319.8%over 5 years+2.7%over 5 years
EPS growth a year, past–+14.9%over 5 years

Margins and returns on capital

CRMDJNJ
Margins and returns on capital
Gross margin77.5%67.6%
Operating margin38.6%–
Net margin15.5%16.2%
ROIC27.3%12.4%
ROE14.9%19.7%

Balance sheet

CRMDJNJ
Balance sheet
Cash$355M$17.2B
Total debt$144.6K$44.7B
Net debt / EBITDA-2.21.1
Interest cover57.2×18.0×

Dividends and buybacks

CRMDJNJ
Dividends and buybacks
Dividend yield–2.0%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield–0.9%
Shareholder yield–2.9%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: CRMD or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, CorMedix or Johnson & Johnson?

By market value, Johnson & Johnson ($642B) is about 1,731.0 times CorMedix ($371M), at today's prices.

How did CRMD and JNJ stock do over the last 10 years?

Since November 21, 2016, CRMD's price moved -45.3% and JNJ's +131.4%. With dividends: CRMD -45.3% (-5.9% a year), JNJ +201.6% (+11.7% a year). Past returns do not predict future ones.

Which pays the higher dividend, CRMD or JNJ?

The dividend yield at today's price is none for CorMedix and 1.98% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

What is the P/E of CRMD and JNJ?

At today's price, the P/E is 5.8 for CRMD and 39.9 for JNJ. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, CorMedix or Johnson & Johnson?

Over the last twelve months, the net margin was 15.5% for CorMedix and 16.2% for Johnson & Johnson, and the operating margin 38.6% and –. Revenue was $412M and $99.3B.

Which is the better investment, CorMedix or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.